How should I intervene for a patient with epilepsy who uses cannabis?

How to Intervene for Marijuana Use in Epilepsy Patients

For patients with epilepsy using cannabis, you should strongly counsel them to discontinue recreational/non-pharmaceutical cannabis products and transition to FDA-approved cannabidiol (Epidiolex) if they have specific epilepsy syndromes, or optimize conventional antiseizure medications if they do not.

Key Clinical Decision Points

Assess the Type of Cannabis Use

Distinguish between:

• Recreational/self-directed cannabis (THC-containing products) - Associated with worse outcomes
• FDA-approved pharmaceutical CBD (Epidiolex) - Evidence-based for specific syndromes
• Non-pharmaceutical CBD/THC products - Unregulated, variable quality

Evidence Against Recreational Cannabis in Epilepsy

The data strongly suggests harm from non-pharmaceutical cannabis use:

• Cannabis use disorder is independently associated with 56% increased likelihood of epilepsy hospitalization 1
• Patients with cannabis use disorder have threefold higher likelihood of emergency admissions for epilepsy 1
• Two documented fatalities occurred in patients using self-directed cannabis therapy as monotherapy, including sudden unexpected death in epilepsy (SUDEP) and seizure-associated drowning 2
• Recent case reports demonstrate temporal association between cannabis use and breakthrough seizures, including potential interference with responsive neurostimulation (RNS) therapy 3

Screen for Cannabis Use Disorder

Evaluate for cannabis use disorder (CUD) using DSM-5 criteria 4. Key symptoms include:

• Irritability, insomnia, headaches during withdrawal 4
• Continued use despite negative consequences
• Failed attempts to cut down
• Early initiation increases risk for developing use disorder 4

Intervention Algorithm

Step 1: Direct Counseling on Risks

Provide specific education about:

• Increased hospitalization risk (56% higher odds) 1
• Risk of breakthrough seizures 3
• Potential pharmacokinetic interactions with prescribed antiseizure medications 3
• Documented mortality cases with self-directed cannabis therapy 2
• Impaired driving ability affecting reaction time and coordination 4

Step 2: Determine Eligibility for FDA-Approved CBD

Epidiolex is FDA-approved ONLY for:

• Lennox-Gastaut syndrome
• Dravet syndrome
• Tuberous sclerosis complex 4

If patient has one of these syndromes: Transition to pharmaceutical-grade Epidiolex under neurologist supervision.

If patient has other epilepsy types: The evidence is insufficient. A 2022 prospective study of high-CBD/low-THC formulations in treatment-resistant epilepsies found no evidence of efficacy for reducing seizures, seizure duration, or rescue medication use 5.

Step 3: Optimize Conventional Antiseizure Medications

For patients without FDA-approved indications for CBD:

• Review medication adherence (noncompliance is a common precipitant of ED visits) 6
• Optimize dosing of current antiseizure medications
• Consider alternative evidence-based antiseizure medications
• Address any substance use lowering seizure threshold 6

Step 4: Address Cannabis Use Disorder if Present

Psychosocial interventions are effective but underutilized:

• Cognitive behavioral therapy is cited as effective treatment 4
• Comprehensive insurance coverage should be pursued for evidence-based CUD treatments 4
• Address barriers including fear of stigma and self-reliance attitudes 4

Critical Pitfalls to Avoid

Do not:

• Assume all cannabis products are equivalent - pharmaceutical CBD differs fundamentally from recreational cannabis
• Ignore THC content - THC may alter neuronal excitability and exacerbate seizures 3
• Accept patient self-direction of cannabis therapy without medical oversight - this has resulted in documented fatalities 2
• Overlook drug interactions - cannabis can affect antiseizure medication levels 3

Common patient misconceptions to address:

• Cannabis is safer because it's "natural" - this belief predicts cannabis use 7
• All CBD products are the same - unregulated products have inadequate quality control 4
• Cannabis has no side effects - patients using cannabis are more likely to believe this incorrectly 7

Special Populations

Pregnant/breastfeeding patients: The U.S. Surgeon General and FDA advise complete avoidance of cannabis in any form, including CBD products, due to negative effects on fetal brain development and increased risk for premature birth 4.

Adolescents: Cannabis use is associated with neuropsychological decline, elevated risk for psychotic disorders, depression, and suicidal ideation 4. Early initiation increases risk for use disorder 4.

Older adults: Higher risk for behavioral health issues (anxiety, depression), increased ED visits, and acute toxicity including sedation and myocardial ischemia 4.

Documentation and Follow-up

Document:

• Current cannabis use patterns (frequency, product type, THC/CBD content if known)
• Screening for cannabis use disorder
• Counseling provided on risks specific to epilepsy
• Plan for transitioning to evidence-based therapy

Schedule close follow-up to monitor seizure control and medication adherence after intervention.